Literature DB >> 1998005

Angiotensin-converting enzyme inhibition reduces neuroblastoma cell growth rate.

L Chen1, R N Re, O Prakash, D Mondal.   

Abstract

Because of the known capacity of angiotensin II to serve as a growth factor in multiple tissues, we elected to study the effects of renin-angiotensin system inhibition on the growth of human SH-SY5Y neuroblastoma cells. Cells were treated with captopril (0.05-5 mg/ml), enalapril, or enalaprilat (0.02-5 mg/ml) or saralasin (0.1-0.25 mg/ml). In all cases, statistically significant reductions in cell growth were seen over 5 days of culture. In additional experiments, captopril and enalaprilat significantly decreased thymidine incorporation into DNA in these cells. The administration of angiotensin II in the presence of captopril partially offset these suppressive effects.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1998005     DOI: 10.3181/00379727-196-43189

Source DB:  PubMed          Journal:  Proc Soc Exp Biol Med        ISSN: 0037-9727


  8 in total

Review 1.  Carcinogenicity of antihypertensive therapy.

Authors:  Ehud Grossman; Franz H Messerli; Uri Goldbourt
Journal:  Curr Hypertens Rep       Date:  2002-06       Impact factor: 5.369

2.  Angiotensin-converting enzyme inhibitor captopril prevents activation-induced apoptosis by interfering with T cell activation signals.

Authors:  C Odaka; T Mizuochi
Journal:  Clin Exp Immunol       Date:  2000-09       Impact factor: 4.330

Review 3.  Carcinogenicity of cardiovascular drugs.

Authors:  E Grossman; F H Messerli; U Goldbourt
Journal:  Curr Hypertens Rep       Date:  1999-06       Impact factor: 5.369

4.  Nuclear-delimited angiotensin receptor-mediated signaling regulates cardiomyocyte gene expression.

Authors:  Artavazd Tadevosyan; Ange Maguy; Louis R Villeneuve; Judith Babin; Arnaud Bonnefoy; Bruce G Allen; Stanley Nattel
Journal:  J Biol Chem       Date:  2010-05-12       Impact factor: 5.157

5.  Experimental and Molecular Modeling Studies on the Complexation of Chromium(III) with the Angiotensin-Converting Enzyme Inhibitor Captopril.

Authors:  Shimaa A Mahmoud; Mohamed Taha; Eman S H Khaled; Walid Hamdy Hassan; Fatma I Abo El-Ela; Ahmed A Abdel-Khalek; Reham A Mohamed
Journal:  ACS Omega       Date:  2022-04-28

6.  Effects of the angiotensin-I converting enzyme inhibitor perindopril on tumor growth and angiogenesis in head and neck squamous cell carcinoma cells.

Authors:  Ryuji Yasumatsu; Torahiko Nakashima; Muneyuki Masuda; Aya Ito; Yuichiro Kuratomi; Takashi Nakagawa; Shizuo Komune
Journal:  J Cancer Res Clin Oncol       Date:  2004-07-27       Impact factor: 4.553

7.  Does Angiotensin-Converting Enzyme Inhibitor and β-Blocker Use Reduce the Risk of Primary Liver Cancer? A Case-Control Study Using the U.K. Clinical Practice Research Datalink.

Authors:  Katrina Wilcox Hagberg; Vikrant V Sahasrabuddhe; Katherine A McGlynn; Susan S Jick
Journal:  Pharmacotherapy       Date:  2016-02-05       Impact factor: 4.705

8.  AT1 receptor is present in glioma cells; its blockage reduces the growth of rat glioma.

Authors:  E Rivera; O Arrieta; P Guevara; A Duarte-Rojo; J Sotelo
Journal:  Br J Cancer       Date:  2001-11-02       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.